IBDEI0K3 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8859,1,4,0)
 ;;=4^E21.3
 ;;^UTILITY(U,$J,358.3,8859,2)
 ;;=^331438
 ;;^UTILITY(U,$J,358.3,8860,0)
 ;;=E83.42^^69^603^21
 ;;^UTILITY(U,$J,358.3,8860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8860,1,3,0)
 ;;=3^Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,8860,1,4,0)
 ;;=4^E83.42
 ;;^UTILITY(U,$J,358.3,8860,2)
 ;;=^5003003
 ;;^UTILITY(U,$J,358.3,8861,0)
 ;;=N25.1^^69^603^25
 ;;^UTILITY(U,$J,358.3,8861,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8861,1,3,0)
 ;;=3^Nephrogenic Diabetes Insipidus
 ;;^UTILITY(U,$J,358.3,8861,1,4,0)
 ;;=4^N25.1
 ;;^UTILITY(U,$J,358.3,8861,2)
 ;;=^5015616
 ;;^UTILITY(U,$J,358.3,8862,0)
 ;;=E27.49^^69^603^2
 ;;^UTILITY(U,$J,358.3,8862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8862,1,3,0)
 ;;=3^Adrenocortical Insufficiency,Other
 ;;^UTILITY(U,$J,358.3,8862,1,4,0)
 ;;=4^E27.49
 ;;^UTILITY(U,$J,358.3,8862,2)
 ;;=^5002743
 ;;^UTILITY(U,$J,358.3,8863,0)
 ;;=E72.09^^69^603^4
 ;;^UTILITY(U,$J,358.3,8863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8863,1,3,0)
 ;;=3^Amino-Acid Transport Disorders,Other
 ;;^UTILITY(U,$J,358.3,8863,1,4,0)
 ;;=4^E72.09
 ;;^UTILITY(U,$J,358.3,8863,2)
 ;;=^5002895
 ;;^UTILITY(U,$J,358.3,8864,0)
 ;;=N25.89^^69^603^23
 ;;^UTILITY(U,$J,358.3,8864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8864,1,3,0)
 ;;=3^Impaired Renal Tubular Function Disorders,Other
 ;;^UTILITY(U,$J,358.3,8864,1,4,0)
 ;;=4^N25.89
 ;;^UTILITY(U,$J,358.3,8864,2)
 ;;=^5015618
 ;;^UTILITY(U,$J,358.3,8865,0)
 ;;=E26.89^^69^603^12
 ;;^UTILITY(U,$J,358.3,8865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8865,1,3,0)
 ;;=3^Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,8865,1,4,0)
 ;;=4^E26.89
 ;;^UTILITY(U,$J,358.3,8865,2)
 ;;=^5002737
 ;;^UTILITY(U,$J,358.3,8866,0)
 ;;=N25.81^^69^603^29
 ;;^UTILITY(U,$J,358.3,8866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8866,1,3,0)
 ;;=3^Secondary Hyperparathyroidism of Renal Origin
 ;;^UTILITY(U,$J,358.3,8866,1,4,0)
 ;;=4^N25.81
 ;;^UTILITY(U,$J,358.3,8866,2)
 ;;=^5015617
 ;;^UTILITY(U,$J,358.3,8867,0)
 ;;=E22.2^^69^603^28
 ;;^UTILITY(U,$J,358.3,8867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8867,1,3,0)
 ;;=3^SIADH
 ;;^UTILITY(U,$J,358.3,8867,1,4,0)
 ;;=4^E22.2
 ;;^UTILITY(U,$J,358.3,8867,2)
 ;;=^5002718
 ;;^UTILITY(U,$J,358.3,8868,0)
 ;;=E87.79^^69^603^10
 ;;^UTILITY(U,$J,358.3,8868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8868,1,3,0)
 ;;=3^Fluid Overload,Other
 ;;^UTILITY(U,$J,358.3,8868,1,4,0)
 ;;=4^E87.79
 ;;^UTILITY(U,$J,358.3,8868,2)
 ;;=^5003025
 ;;^UTILITY(U,$J,358.3,8869,0)
 ;;=E21.0^^69^603^27
 ;;^UTILITY(U,$J,358.3,8869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8869,1,3,0)
 ;;=3^Primary Hyperparathyroidism
 ;;^UTILITY(U,$J,358.3,8869,1,4,0)
 ;;=4^E21.0
 ;;^UTILITY(U,$J,358.3,8869,2)
 ;;=^331439
 ;;^UTILITY(U,$J,358.3,8870,0)
 ;;=E87.71^^69^603^30
 ;;^UTILITY(U,$J,358.3,8870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8870,1,3,0)
 ;;=3^Transfusion Associated Circulatory Overload
 ;;^UTILITY(U,$J,358.3,8870,1,4,0)
 ;;=4^E87.71
 ;;^UTILITY(U,$J,358.3,8870,2)
 ;;=^5003024
 ;;^UTILITY(U,$J,358.3,8871,0)
 ;;=D63.1^^69^604^1
 ;;^UTILITY(U,$J,358.3,8871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8871,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,8871,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,8871,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,8872,0)
 ;;=I12.0^^69^604^9
 ;;^UTILITY(U,$J,358.3,8872,1,0)
 ;;=^358.31IA^4^2
